The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumours following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumours. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.本發明係關於用於人類癌症治療之重組抗體領域。更特定言之,本發明提供對人類EGFR具有兩種獨特的非重疊結合特異性之抗體組成物的用途。該抗體組成物可在用其他抗EGFR抗體治療後有效於治療癌症,無論該癌症是否在該先前治療期間或之後顯示進展皆然。該抗體組成物亦可用於在用本發明之抗體組成物進行第一線治療後重複治療復發性腫瘤,因為該組成物不會導致抗性腫瘤選擇性。另一治療用途為使用本發明之抗體組成物治療對已知抗EGFR抗體具有抗性之癌症。
